Pfizer delivered first-quarter sales and profit that topped forecasts as cancer treatments offset fading appetite for Covid products. Shares gained 0.7% in premarket trading, signaling investor relief that Pfizer can stabilize top-line performance while digesting a postpandemic hangover. Management sees momentum building around therapies that command premium pricing and durable use.

Demand for vaccines and acute Covid care has plunged, forcing the company to replace lost revenue with complex, long-course oncology and obesity medicines. Weight-loss acquisitions and new molecules represent a heavy bet on chronic markets where competition is intensifying and payers scrutinize cost. Investors must weigh execution risk against potential margin expansion.

Chief Executive Albert Bourla said the start to 2026 affirms strategy, pointing to oncology and obesity as arenas where the firm can lead. No timeline is given for turning big bets into durable profit. Pfizer is retooling its portfolio toward higher-value therapies to lock in recovery gains.